Strategies for intranasal delivery of vaccines

Drug Delivery and Translational Research

Volumn 3, Issue 1, 2013, Pages 100-109

  Zaman, Mehfuz ^a   Chandrudu, Saranya ^a   Toth, Istvan ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Immunity; Mucosal adjuvant; Nasal vaccine; Vaccine delivery

Indexed keywords

ADJUVANT; ALGINIC ACID; CARBOMER; CHITOSAN; DNA VACCINE; FOOT AND MOUTH DISEASE VACCINE; INFLUENZA VACCINE; ISCOM; LIPOPEPTIDE; LIPOSOME; LIVE VACCINE; PEPTIDE VACCINE; POLYGLACTIN; VACCINE; VIROSOME;

ANTIGEN PRESENTATION; BIOCOMPATIBILITY; CHEMICAL STRUCTURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; LYMPHOID TISSUE; MUCOADHESION; NONHUMAN; NOSE MUCOSA; PANDEMIC INFLUENZA; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA; UNSPECIFIED SIDE EFFECT;

EID: 84875523596     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-012-0085-z     Document Type: Review

References (114)

1. Ricciardi W. The old Edward Jenner and the new public health: the future of vaccines in Europe. Eur J Public Health. 2008; 18(4): 353.
2. Ellner PD. Smallpox: gone but not forgotten. Infection. 1998; 26(5): 263-9.
3. Obregon R, Chitnis K, Morry C, Feek W, Bates J, Galway M, et al. Achieving polio eradication: a review of health communication evidence and lessons learned in India and Pakistan. Bull World Health Organ. 2009; 87(8): 624-30.
4. Almeida AJ, Alpar HO. Nasal delivery of vaccines. J Drug Target. 1996; 3(6): 455-67.
5. Boyaka PN, Tafaro A, Fischer R, Leppla SH, Fujihashi K, McGhee JR. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol. 2003; 170(11): 5636-43.
6. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006; 6(2): 148-58.
7. Zuercher AW, Coffin SE, Thurnheer MC, Fundova P, Cebra JJ. Nasal-associated lymphoid tissue is a mucosal inductive site for virus-specific humoral and cellular immune responses. J Immunol. 2002; 168(4): 1796-803.
8. Hiroi T, Iwatani K, Iijima H, Kodama S, Yanagita M, Kiyono H. Nasal immune system: distinctive Th0 and Th1/Th2 type environments in murine nasal-associated lymphoid tissues and nasal passage, respectively. Eur J Immunol. 1998; 28(10): 3346-53.
9. Wu HY, Nguyen HH, Russell MW. Nasal lymphoid tissue (NALT) as a mucosal immune inductive site. Scand J Immunol. 1997; 46(5): 506-13.
10. Cesta MF. Normal structure, function, and histology of mucosa-associated lymphoid tissue. Toxicol Pathol. 2006; 34(5): 599-608.
11. Brandtzaeg P. Immune functions of nasopharyngeal lymphoid tissue. Adv Otorhinolaryngol. 2011; 72: 20-4.
12. Whaley KJ, Zeitlin L. Preventing transmission: plant-derived microbicides and mucosal vaccines for reproductive health. Vaccine. 2005; 23(15): 1819-22.
13. Corr SC, Gahan CC, Hill C. M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis. FEMS Immunol Med Microbiol. 2008; 52(1): 2-12.
14. Guy B. Evaluation of events occurring at mucosal surfaces: techniques used to collect and analyze mucosal secretions and cells. Clin Diagn Lab Immunol. 2002; 9(4): 753-62.
15. Fujimura Y. Evidence of M cells as portals of entry for antigens in the nasopharyngeal lymphoid tissue of humans. Virchows Arch. 2000; 436(6): 560-6.
16. Davis SS. Nasal vaccines. Adv Drug Deliv Rev. 2001; 51(1-3): 21-42.
17. Ogasawara N, Kojima T, Go M, Takano K, Kamekura R, Ohkuni T, et al. Epithelial barrier and antigen uptake in lymphoepithelium of human adenoids. Acta Otolaryngol. 2011; 131(2): 116-23.
18. Johansen FE, Kaetzel CS. Regulation of the polymeric immunoglobulin receptor and IgA transport: new advances in environmental factors that stimulate pIgR expression and its role in mucosal immunity. Mucosal Immunol. 2011; 4(6): 598-602.
19. Jabbal-Gill I. Nasal vaccine innovation. J Drug Target. 2010; 18(10): 771-86.
20. Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 1998; 338(20): 1405-12.
21. Izurieta HS, Haber P, Wise RP, Iskander J, Pratt D, Mink C, et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA. 2005; 294(21): 2720-5.
22. Velasquez LS, Shira S, Berta AN, Kilbourne J, Medi BM, Tizard I, et al. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. Vaccine. 2011; 29(32): 5221-31.
23. Garg NK, Mangal S, Khambete H, Tyagi RK. Mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymers. Recent Pat Drug Deliv Formul. 2010; 4(2): 114-28.
24. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release. 2003; 87(1-3): 187-98.
25. Yang J, Zhao J, Fang Y. Calorimetric studies of the interaction between sodium alginate and sodium dodecyl sulfate in dilute solutions at different pH values. Carbohydr Res. 2008; 343(4): 719-25.
26. Sahoo S, Chakraborti CK, Mishra SC. Qualitative analysis of controlled release ciprofloxacin/carbopol 934 mucoadhesive suspension. J Adv Pharm Technol Res. 2011; 2(3): 195-204.
27. Rajinikanth PS, Sankar C, Mishra B. Sodium alginate microspheres of metoprolol tartrate for intranasal systemic delivery: development and evaluation. Drug Deliv. 2003; 10(1): 21-8.
28. Bertram U, Bodmeier R. In situ gelling, bioadhesive nasal inserts for extended drug delivery: in vitro characterization of a new nasal dosage form. Eur J Pharm Sci. 2006; 27(1): 62-71.
29. Singh M, O'Hagan D. The preparation and characterization of polymeric antigen delivery systems for oral administration. Adv Drug Deliv Rev. 1998; 34(2-3): 285-304.
30. Sedgmen BJ, Meeusen EN, Lofthouse SA. Alternative routes of mucosal immunization in large animals. Immunol Cell Biol. 2004; 82(1): 10-6.
31. Rebelatto MC, Guimond P, Bowersock TL, HogenEsch H. Induction of systemic and mucosal immune response in cattle by intranasal administration of pig serum albumin in alginate microparticles. Vet Immunol Immunopathol. 2001; 83(1-2): 93-105.
32. Makhlof A, Fujimoto S, Tozuka Y, Takeuchi H. In vitro and in vivo evaluation of WGA-carbopol modified liposomes as carriers for oral peptide delivery. Eur J Pharm Biopharm. 2011; 77(2): 216-24.
33. Coucke D, Schotsaert M, Libert C, Pringels E, Vervaet C, Foreman P, et al. Spray-dried powders of starch and crosslinked poly(acrylic acid) as carriers for nasal delivery of inactivated influenza vaccine. Vaccine. 2009; 27(8): 1279-86.
34. Alpar HO, Somavarapu S, Atuah KN, Bramwell VW. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev. 2005; 57(3): 411-30.
35. Witschi C, Mrsny RJ. In vitro evaluation of microparticles and polymer gels for use as nasal platforms for protein delivery. Pharm Res. 1999; 16(3): 382-90.
36. Wen ZS, Xu YL, Zou XT, Xu ZR. Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice. Mar Drugs. 2011; 9(6): 1038-55.
37. Rossi S, Ferrari F, Bonferoni MC, Caramella C. Characterization of chitosan hydrochloride-mucin rheological interaction: influence of polymer concentration and polymer: mucin weight ratio. Eur J Pharm Sci. 2001; 12(4): 479-85.
38. Ferrari F, Rossi S, Bonferoni MC, Caramella C, Karlsen J. Characterization of rheological and mucoadhesive properties of three grades of chitosan hydrochloride. Farmaco. 1997; 52(6-7): 493-7.
39. Harding SE. Mucoadhesive interactions. Biochem Soc Trans. 2003; 31(Pt 5): 1036-41.
40. Fujimura Y, Akisada T, Harada T, Haruma K. Uptake of microparticles into the epithelium of human nasopharyngeal lymphoid tissue. Med Mol Morphol. 2006; 39(4): 181-6.
41. Rauw F, Gardin Y, Palya V, Anbari S, Gonze M, Lemaire S, et al. The positive adjuvant effect of chitosan on antigen-specific cell-mediated immunity after chickens vaccination with live Newcastle disease vaccine. Vet Immunol Immunopathol. 2010; 134(3-4): 249-58.
42. Ghendon Y, Markushin S, Krivtsov G, Akopova I. Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines. Arch Virol. 2008; 153(5): 831-7.
43. Verheul RJ, Hagenaars N, van Es T, van Gaal EV, de Jong PH, Bruijns S, et al. A step-by-step approach to study the influence of N-acetylation on the adjuvanticity of N, N, N-trimethyl chitosan (TMC) in an intranasal nanoparticulate influenza virus vaccine. Eur J Pharm Sci. 2012; 45(4): 467-74.
44. Ranaldi G, Marigliano I, Vespignani I, Perozzi G, Sambuy Y. The effect of chitosan and other polycations on tight junction permeability in the human intestinal Caco-2 cell line(1). J Nutr Biochem. 2002; 13(3): 157-67.
45. Svindland SC, Jul-Larsen A, Pathirana R, Andersen S, Madhun A, Montomoli E, et al. The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine. Influenza Other Respi Viruses. 2012; 6(2): 90-100.
46. Sui Z, Chen Q, Fang F, Zheng M, Chen Z. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. Vaccine. 2010; 28(48): 7690-8.
47. McNeela EA, O'Connor D, Jabbal-Gill I, Illum L, Davis SS, Pizza M, et al. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine. 2000; 19(9-10): 1188-98.
48. Saenz L, Neira-Carrillo A, Paredes R, Cortes M, Bucarey S, Arias JL. Chitosan formulations improve the immunogenicity of a GnRH-I peptide-based vaccine. Int J Pharm. 2009; 369(1-2): 64-71.
49. Slutter B, Bal S, Keijzer C, Mallants R, Hagenaars N, Que I, et al. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine. 2010; 28(38): 6282-91.
50. Xu W, Shen Y, Jiang Z, Wang Y, Chu Y, Xiong S. Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection. Vaccine. 2004; 22(27-28): 3603-12.
51. Aspden TJ, Mason JD, Jones NS, Lowe J, Skaugrud O, Illum L. Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J Pharm Sci. 1997; 86(4): 509-13.
52. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev. 2001; 51(1-3): 81-96.
53. Sharma S, Mukkur TK, Benson HA, Chen Y. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J Pharm Sci. 2009; 98(3): 812-43.
54. Heurtault B, Frisch B, Pons F. Liposomes as delivery systems for nasal vaccination: strategies and outcomes. Expert Opin Drug Deliv. 2010; 7(7): 829-44.
55. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev. 2007; 59(6): 478-90.
56. Takata S, Ohtani O, Watanabe Y. Lectin binding patterns in rat nasal-associated lymphoid tissue (NALT) and the influence of various types of lectin on particle uptake in NALT. Arch Histol Cytol. 2000; 63(4): 305-12.
57. Zho F, Neutra MR. Antigen delivery to mucosa-associated lymphoid tissues using liposomes as a carrier. Biosci Rep. 2002; 22(2): 355-69.
58. Henriksen-Lacey M, Korsholm KS, Andersen P, Perrie Y, Christensen D. Liposomal vaccine delivery systems. Expert Opin Drug Deliv. 2011; 8(4): 505-19.
59. Khatri K, Goyal AK, Gupta PN, Mishra N, Mehta A, Vyas SP. Surface modified liposomes for nasal delivery of DNA vaccine. Vaccine. 2008; 26(18): 2225-33.
60. Ishii M, Kojima N. Mucosal adjuvant activity of oligomannose-coated liposomes for nasal immunization. Glycoconj J. 2010; 27(1): 115-23.
61. Tafaghodi M, Jaafari MR, Tabassi SA. Nasal immunization studies by cationic, fusogenic and cationic-fusogenic liposomes encapsulated with tetanus toxoid. Curr Drug Deliv. 2008; 5(2): 108-13.
62. Pearse MJ, Drane D. ISCOMATRIX adjuvant for antigen delivery. Adv Drug Deliv Rev. 2005; 57(3): 465-74.
63. Duewell P, Kisser U, Heckelsmiller K, Hoves S, Stoitzner P, Koernig S, et al. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. J Immunol. 2011; 187(1): 55-63.
64. Schnurr M, Orban M, Robson NC, Shin A, Braley H, Airey D, et al. ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II. J Immunol. 2009; 182(3): 1253-9.
65. Drane D, Gittleson C, Boyle J, Maraskovsky E. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Rev Vaccines. 2007; 6(5): 761-72.
66. Coulter A, Harris R, Davis R, Drane D, Cox J, Ryan D, et al. Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine. Vaccine. 2003; 21(9-10): 946-9.
67. Chen M, Hu KF, Rozell B, Orvell C, Morein B, Liljestrom P. Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus. J Immunol. 2002; 169(6): 3208-16.
68. Kodama S, Hirano T, Noda K, Umemoto S, Suzuki M. Nasal immunization with plasmid DNA encoding P6 protein and immunostimulatory complexes elicits nontypeable Haemophilus influenzae-specific long-term mucosal immune responses in the nasopharynx. Vaccine. 2011; 29(10): 1881-90.
69. Pandey RS, Dixit VK. Evaluation of ISCOM vaccines for mucosal immunization against hepatitis B. J Drug Target. 2010; 18(4): 282-91.
70. Walker RI. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine. 1994; 12(5): 387-400.
71. Kammer AR, Amacker M, Rasi S, Westerfeld N, Gremion C, Neuhaus D, et al. A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses. Vaccine. 2007; 25(41): 7065-74.
72. Bungener L, Huckriede A, Wilschut J, Daemen T. Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMs. Biosci Rep. 2002; 22(2): 323-38.
73. Cusi MG, Zurbriggen R, Correale P, Valassina M, Terrosi C, Pergola L, et al. Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity. Vaccine. 2002; 20(29-30): 3436-42.
74. Cech PG, Aebi T, Abdallah MS, Mpina M, Machunda EB, Westerfeld N, et al. Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children. PLoS One. 2011; 6(7): e22273.
75. Cusi MG, Terrosi C, Savellini GG, Di Genova G, Zurbriggen R, Correale P. Efficient delivery of DNA to dendritic cells mediated by influenza virosomes. Vaccine. 2004; 22(5-6): 735-9.
76. Angel J, Chaperot L, Molens JP, Mezin P, Amacker M, Zurbriggen R, et al. Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells. Vaccine. 2007; 25(19): 3913-21.
77. Gluck U, Gebbers JO, Gluck R. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J Virol. 1999; 73(9): 7780-6.
78. Gluck R, Mischler R, Durrer P, Furer E, Lang AB, Herzog C, et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J Infect Dis. 2000; 181(3): 1129-32.
79. Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, Roger MG, et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity. 2011; 34(2): 269-80.
80. Bessler WG, Heinevetter L, Wiesmuller KH, Jung G, Baier W, Huber M, et al. Bacterial cell wall components as immunomodulators-I. Lipopeptides as adjuvants for parenteral and oral immunization. Int J Immunopharmacol. 1997; 19(9-10): 547-50.
81. Bessler WG, Jung G. Synthetic lipopeptides as novel adjuvants. Res Immunol. 1992; 143(5): 548-53. discussion 79-80.
82. Bessler WG, Baier W, vd Esche U, Hoffmann P, Heinevetter L, Wiesmuller KH et al. Bacterial lipopeptides constitute efficient novel immunogens and adjuvants in parenteral and oral immunization. Behring Inst Mitt. 1997(98): 390-9.
83. Muller MR, Wiesmuller KH, Jung G, Loop T, Humar M, Pfannes SD, et al. Lipopeptide adjuvants: monitoring and comparison of P3CSK4- and LPS-induced gene transcription. Int Immunopharmacol. 2002; 2(8): 1065-77.
84. Kargakis M, Zevgiti S, Krikorian D, Sakarellos-Daitsiotis M, Sakarellos C, Panou-Pomonis E. A palmitoyl-tailed sequential oligopeptide carrier for engineering immunogenic conjugates. Vaccine. 2007; 25(37-38): 6708-12.
85. Yong M, Mitchell D, Caudron A, Toth I, Olive C. Expression of maturation markers on murine dendritic cells in response to group A streptococcal lipopeptide vaccines. Vaccine. 2009; 27(25-26): 3313-8.
86. Barrenschee M, Lex D, Uhlig S. Effects of the TLR2 agonists MALP-2 and Pam3Cys in isolated mouse lungs. PLoS One. 2010; 5(11): e13889.
87. Zeng W, Eriksson E, Chua B, Grollo L, Jackson DC. Structural requirement for the agonist activity of the TLR2 ligand Pam2Cys. Amino Acids. 2010; 39(2): 471-80.
88. Zhu X, Ramos TV, Gras-Masse H, Kaplan BE, BenMohamed L. Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. Eur J Immunol. 2004; 34(11): 3102-14.
89. Zaman M, Abdel-Aal AB, Phillipps KS, Fujita Y, Good MF, Toth I. Structure-activity relationship of lipopeptide group A streptococcus (GAS) vaccine candidates on Toll-like receptor 2. Vaccine. 2010; 28(10): 2243-8.
90. Zeng W, Ghosh S, Lau YF, Brown LE, Jackson DC. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol. 2002; 169(9): 4905-12.
91. Batzloff MR, Hartas J, Zeng W, Jackson DC, Good MF. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization. J Infect Dis. 2006; 194(3): 325-30.
92. Deliyannis G, Kedzierska K, Lau YF, Zeng W, Turner SJ, Jackson DC, et al. Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. Eur J Immunol. 2006; 36(3): 770-8.
93. BenMohamed L, Krishnan R, Auge C, Primus JF, Diamond DJ. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology. 2002; 106(1): 113-21.
94. Zhang X, Chentoufi AA, Dasgupta G, Nesburn AB, Wu M, Zhu X, et al. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol. 2009; 2(2): 129-43.
95. Zaman M, Abdel-Aal AB, Fujita Y, Phillipps KS, Batzloff MR, Good MF, et al. Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationship. PLoS One. 2012; 7(1): e30146.
96. Abdel-Aal AB, Zaman M, Fujita Y, Batzloff MR, Good MF, Toth I. Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components. J Med Chem. 2010; 53(22): 8041-6.
97. Abdel-Aal AB, Al-Isae K, Zaman M, Toth I. Simple synthetic toll-like receptor 2 ligands. Bioorg Med Chem Lett. 2011; 21(19): 5863-5.
98. Raghuwanshi D, Mishra V, Das D, Kaur K, Suresh MR. Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein. Mol Pharm. 2012; 9(4): 946-56.
99. Shim BS, Park SM, Quan JS, Jere D, Chu H, Song MK, et al. Intranasal immunization with plasmid DNA encoding spike protein of SARS-coronavirus/polyethylenimine nanoparticles elicits antigen-specific humoral and cellular immune responses. BMC Immunol. 2010; 11: 65.
100. Torrieri-Dramard L, Lambrecht B, Ferreira HL, van den Berg T, Klatzmann D, Bellier B. Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses. Mol Ther. 2011; 19(3): 602-11.
101. Wang G, Pan L, Zhang Y, Wang Y, Zhang Z, Lu J, et al. Intranasal delivery of cationic PLGA nano/microparticles-loaded FMDV DNA vaccine encoding IL-6 elicited protective immunity against FMDV challenge. PLoS One. 2011; 6(11): e27605.
102. Moschos SA, Bramwell VW, Somavarapu S, Alpar HO. Adjuvant synergy: the effects of nasal coadministration of adjuvants. Immunol Cell Biol. 2004; 82(6): 628-37.
103. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med. 2005; 11(4 Suppl): S45-53.
104. Fujkuyama Y, Tokuhara D, Kataoka K, Gilbert RS, McGhee JR, Yuki Y, et al. Novel vaccine development strategies for inducing mucosal immunity. Expert Rev Vaccines. 2012; 11(3): 367-79.
105. Disis ML, Rinn K, Knutson KL, Davis D, Caron D, dela Rosa C, et al. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood. 2002; 99(8): 2845-50.
106. Nierkens S, den Brok MH, Garcia Z, Togher S, Wagenaars J, Wassink M, et al. Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells. Cancer Res. 2011; 71(20): 6428-37.
107. Moldoveanu Z, Love-Homan L, Huang WQ, Krieg AM. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine. 1998; 16(11-12): 1216-24.
108. McCluskie MJ, Weeratna RD, Krieg AM, Davis HL. CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine. 2000; 19(7-8): 950-7.
109. Kataoka K, Fujihashi K, Oma K, Fukuyama Y, Hollingshead SK, Sekine S, et al. The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia. Infect Immun. 2011; 79(7): 2819-28.
110. Kim KH, Kim DI, Kim SH, Jung EM, Kang JH, Jeung EB, et al. Trans-10, cis-12-conjugated linoleic acid attenuates tumor necrosis factor-alpha production by lipopolysaccharide-stimulated porcine peripheral blood mononuclear cells through induction of interleukin-10. Cytokine. 2011; 56(2): 224-30.
111. Persing DH, Coler RN, Lacy MJ, Johnson DA, Baldridge JR, Hershberg RM, et al. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. 2002; 10(10 Suppl): S32-7.
112. Childers NK, Miller KL, Tong G, Llarena JC, Greenway T, Ulrich JT, et al. Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen. Infect Immun. 2000; 68(10): 5509-16.
113. Helander A, Silvey KJ, Mantis NJ, Hutchings AB, Chandran K, Lucas WT, et al. The viral sigma1 protein and glycoconjugates containing alpha2-3-linked sialic acid are involved in type 1 reovirus adherence to M cell apical surfaces. J Virol. 2003; 77(14): 7964-77.
114. Wu Y, Wang X, Csencsits KL, Haddad A, Walters N, Pascual DW. M cell-targeted DNA vaccination. Proc Natl Acad Sci U S A. 2001; 98(16): 9318-23.